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Sirs: We would like to thank Dr. Wiwanitkit for his interest
in our manuscript [1]. We agree that markers in heart
failure like NT-proBNP and galectin-3 may be inﬂuenced
by thyroid dysfunction [2]. In the diagnostic work-up in
patients with heart failure thyroid function tests are rou-
tinely measured as advised by the European Society of
Cardiology [3]. Before entering the DEAL-HF study,
patients were extensively screened and tested according to
this guideline. Patients with untreated thyroid disease were
ineligible for participation in the trial. In addition, also
patients with an active malignant disease were excluded
[4]. During follow-up, 98 patients died. The majority of
patients died from a cardiovascular cause, including 42
from worsening heart failure and 36 from sudden cardiac
death. Twenty patients died from a non-cardiovascular
cause. The median galectin-3 levels did not differ between
the three groups (p = 0.54).
We do agree that laboratory quality control is an
important issue and that interference in sample collection
and laboratory analysis should be avoided. Laboratories
involved in our study have international quality certiﬁcates.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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